HER2 Support Group Forums - View Single Post - news on trastuzumab-dm1/ itsa GO

runtolive · 10-14-2008, 03:02 PM

Genentech announced it made a Phase III "go" decision to study Trastuzumab-DM1 (T-DM1) as a potential second-line treatment for HER2-positive metastatic breast cancer.

In the third quarter of 2008, the company initiated enrollment in two Phase II studies of T-DM1 as potential first-line and third-line treatments for patients with HER2-positive metastatic breast cancer.

run to live

10-14-2008, 03:02 PM	#1
runtolive Senior Member Join Date: Nov 2007 Posts: 210	news on trastuzumab-dm1/ itsa GO Genentech announced it made a Phase III "go" decision to study Trastuzumab-DM1 (T-DM1) as a potential second-line treatment for HER2-positive metastatic breast cancer. In the third quarter of 2008, the company initiated enrollment in two Phase II studies of T-DM1 as potential first-line and third-line treatments for patients with HER2-positive metastatic breast cancer. run to live